Interpace Biosciences (IDXG) investor relations material

Executive summary

• Q2 2026 revenue was $9.1M, down 1% year-over-year, reflecting a transition to thyroid-only diagnostics after discontinuing PancraGEN in May 2025, with focus on ThyGeNEXT® and ThyraMIR® v2 tests.

• Thyroid revenue grew 9% year-over-year, with test volume up 6% and trailing twelve-month thyroid revenue reaching $36.1M, up 11% on a comparable basis.

• Net income for Q2 2026 was $0.2M, compared to a net loss of $0.6M in Q2 2025; net income for the first half was $0.9M, down from $1.0M in the prior year.

• Operational efficiency gains were driven by laboratory automation and AI-enabled productivity initiatives, supporting margin expansion.

Financial highlights

• Gross profit margin improved to 62% in Q2 2026 from 57% in Q2 2025, and to 64% for the first half of 2026 from 61% in the prior year.

• Operating income from continuing operations was $0.3M in Q2 2026 (vs. a $0.5M loss in Q2 2025) and $1.4M for the first half (flat year-over-year).

• Adjusted EBITDA for Q2 2026 was $0.7M (8% margin), up from $0.2M (3%) pro forma in Q2 2025; for the first half, Adjusted EBITDA was $2.3M, down from $2.5M year-over-year.

• Cash and cash equivalents were $2.7M as of June 30, 2026, with positive operating cash flow of $0.4M for the first half.

Outlook and guidance

• Management expects current cash and forecasted receipts to cover anticipated needs for the next twelve months.

• Strategic alternatives and additional funding options are being explored, including equity, debt, and potential Nasdaq uplisting.

• Management expects continued margin expansion as automation and AI initiatives scale with volume growth.

• New pancreatic cancer test development is underway, but commercialization and reimbursement timelines remain uncertain and no revenue contribution is expected in 2026.